Hosted on MSN12mon
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
The experimental obesity drug, dubbed taldefgrobep alfa (BHVN-2000), could prevent muscle loss while helping shed weight. The company highlights that 20%-50% of the weight loss with GLP-1 drugs is ...
ADVFN16d
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
About Taldefgrobep alfa Taldefgrobep alfa is a fully human recombinant protein specifically designed to inhibit both myostatin and activin receptor signaling. By blocking the formation of the ...